AmCad BioMed Corporation reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was TWD 17.23 million compared to TWD 11.73 million a year ago. Net loss was TWD 7.73 million compared to TWD 11.05 million a year ago. Basic loss per share from continuing operations was TWD 0.15 compared to TWD 0.21 a year ago.